Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma

Published:2018-12-05 Issue:5 Volume:184 Page:744-752
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Umakanthan Jayadev M.¹^ORCID,Iqbal Javeed²,Batlevi Connie L.³,Bouska Alyssa²,Smith Lynette M.⁴,Shostrom Valerie⁴,Nutsch Heather¹,William Basem M.⁵,Gregory Bociek R.¹,Lunning Matthew¹,Bierman Philip¹,Younes Anas³,Armitage James O.¹,Vose Julie M.¹

Affiliation:

1. Division of Oncology & Hematology; University of Nebraska Medical Center; Omaha NE USA

2. Department of Pathology and Microbiology; University of Nebraska Medical Center; Omaha NE USA

3. Lymphoma Service; Memorial Sloan-Kettering Cancer Center; New York NY USA

4. Department of Biostatistics; University of Nebraska Medical Center; Omaha NE USA

5. Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center (OSUCCC-James); The Ohio State University; Columbus OH USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15702/fullpdf

Reference44 articles.

1. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets;Bouska;Blood,2017a

2. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma;Bouska;Leukemia,2017b

3. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate;Brave;Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,2008

4. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma;Chen;Blood,2008

5. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

2. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

3. Extranodal lymphoma: pathogenesis, diagnosis and treatment;Molecular Biomedicine;2023-09-18

4. SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target;Clinical Lymphoma Myeloma and Leukemia;2023-08

5. Early phase clinical trials in oncology: Realising the potential of seamless designs;European Journal of Cancer;2023-08